Stanley-Laman Group’s Regenxbio RGNX Stock Holding History

Stanley-Laman Group’s Portfolio RGNX Stock Details RGNX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-11,114	Closed	-$252K	–	254
2022 Q4	$252K	Buy	+11,114	New	+$251K	0.05%	189

Other funds holding RGNX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

ACM

Aquilo Capital Management San Francisco, California $55.8M AUM 41.76% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Stanley-Laman Group's RGNX Position: Q1 2023 in Review

Stanley-Laman Group sold out of Regenxbio (RGNX) in Q1 2023, closing a stake of 11,114 shares — an estimated $252K sold.

Stanley-Laman Group first reported a position in RGNX in Q4 2022 and held it in 1 quarter. The position peaked at $252K in Q4 2022. 174 funds tracked by Wall St. Rank hold RGNX as of Q1 2023.

Stanley-Laman Group reported no remaining Regenxbio position as of Q1 2023 after selling out during the quarter.
Stanley-Laman Group sold 11,114 Regenxbio shares in Q1 2023, an estimated $252K.
Stanley-Laman Group first reported a position in Regenxbio in Q4 2022 and held it in 1 quarter.
Stanley-Laman Group's Regenxbio position peaked at $252K in Q4 2022.
174 funds tracked by Wall St. Rank held Regenxbio as of Q1 2023.

Based on Stanley-Laman Group's 13F filing for Q1 2023, filed 18 Apr 2023.